Weight loss drugs drive protein boom

The popularity of GLP-1 weight loss drugs is driving a major boom in protein-infused products. However, shoppers are increasingly scrutinizing labels for hidden additives and exaggerated claims.

Insights:
Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey

Weight-loss drugs are supercharging demand for high-protein foods, with users projected to spend 11% more on protein items. That surge is triggering intense consumer skepticism over whether products actually deliver on their health claims.

IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.